{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-095838","form_type":"8-K","ticker":"TCRX","cik":"0001783328","company_name":"TScan Therapeutics, Inc.","filed_at":"2023-04-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.549989+00:00","generated_at":"2026-06-17T04:16:37.228113+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TScan Therapeutics adds Dr. Barbara Klencke to board and promotes three to SVP","bullets":["Dr. Barbara Klencke appointed to board effective April 6, 2023; granted option for 9,146 shares vesting over 36 months.","Klencke brings 20+ years oncology drug development; was CMO of Sierra Oncology (acquired by GSK in 2022).","Shrikanta Chattopadhyay promoted to SVP, Medical, Translational Medicine; 15+ years experience.","Ann Hargraves promoted to SVP, Human Resources; previously led HR at Keurig and founded Mindset Consulting.","Ray Lockard promoted to SVP, Technical Operations and Quality; over 25 years in manufacturing and supply chain."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-095838","json":"https://secwatch.observer/filing/0001193125-23-095838.json","markdown":"https://secwatch.observer/filing/0001193125-23-095838.md","text":"https://secwatch.observer/filing/0001193125-23-095838.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523095838/0001193125-23-095838-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523095838/d494333d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T04:16:37.228113+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aa53e7ed3c","claim":"Barbara Klencke was appointed as Director at TScan Therapeutics, Inc..","evidence_excerpt":"On April 6, 2023, the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “Company”) appointed Barbara Klencke, M.D., to the Board, effective April 6, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1783328/000119312523095838/0001193125-23-095838-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}